| |
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
Today’s Big NewsApr 24, 2024 |
| By Fraiser Kansteiner While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks, the CEO admitted Wednesday that there’s still “a lot of work to do” as the biotech plugs ahead with its “Fit for Growth” savings initiative. |
|
|
|
By Nick Paul Taylor Roche has performed a little light spring cleaning, sweeping a pair of phase 1 solid tumor drugs and an early-stage psychiatric disorder prospect out of the door as part of its update for the first quarter. The culls are part of a broader refocusing that has removed 20% of new molecules from the pipeline in recent quarters. |
By Gabrielle Masson What does it feel like to be a woman CEO in biotech? An island, according to former Gossamer Bio CEO and co-founder Sheila Gujrathi, M.D. |
By Conor Hale The latest green lights add cardiac and lung-focused programs to the company’s bladder, hip and thyroid scanning options. |
|
Tuesday, May 7, 2024 | 11 ET / 8 am PT This webinar dives into challenges and strategies in commercializing cell and gene therapies. Experts explore process standardization, treatment tracking tech, network channel strategy, and scaling for commercial success in this promising but complex field. Register now. 
|
|
By Zoey Becker The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. But thanks to blockbuster meds across wider disease areas and other challenges, the lucrative market may soon slow down for the first time in years. |
By Annalee Armstrong To be a better neuroscience company, Biogen is going to diversify—outside of the therapeutic area that has in recent years defined the company. |
By Nick Paul Taylor As medical aesthetic rivals sign up galaxies of star spokespeople, AbbVie continues to go in the opposite direction and focus on the everyday users of its beauty products. The drugmaker is holding another open casting call for Allergan Aesthetics to find the next faces of campaigns for products including Botox. |
By Kevin Dunleavy How much impact has the approval of high-dose Eylea had on the upward trajectory of Roche’s Vabysmo? Not much, according to sales figures released by Roche. |
By Ben Adams AstraZeneca and Merck were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. |
By Angus Liu Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, Day One's newcomer boasts an FDA approval covering a broader patient population. |
By Nick Paul Taylor A Chiesi survey has found widespread unmet needs among Fabry disease patients taking drugs such as Sanofi’s Fabrazyme, pointing to how the Italian drugmaker can muscle in on the market. |
By Annalee Armstrong If you asked an AI to generate a brand-new drug discovery biotech with a team of some of the biggest names in the biz for you, it couldn’t dream up one like Xaira Therapeutics. The company emerged Tuesday with $1 billion in committed funding. |
By Annalee Armstrong Vertex’s cystic fibrosis triple combo is poised to become the top selling orphan drug in terms of net present value, amid shifting sentiments in the pharma industry for rare disease drugs, according to Evaluate. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness. |
|
|---|
|
|
|
Wednesday, May 13, 2024 | 10 ET / 7 am PT This webinar unveils AI's transformative role in life sciences, presented by industry experts. Learn how AI process automation expedites drug development, ensures regulatory compliance, enhances communication, and boosts collaboration. Register now. 
|
|
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
